Objective:

To highlight key presentations and studies expected at the upcoming ASCO annual meeting.

Key Findings:

• Daraxonrasib showed a median overall survival of 13.2 months compared to 6.7 months for standard chemotherapy.
• Daraxonrasib reduced the risk of death by 60% compared to chemotherapy.
• Expectations for ivonescimab include a hazard ratio of 0.70 to 0.80, indicating a 20%-30% reduction in risk of death.

Interpretation:

The results from these studies could have significant implications for treatment standards in pancreatic cancer and lung cancer.

Limitations:

• Details on subpopulations and safety of daraxonrasib are still pending.
• The HARMONi-6 study was conducted entirely in China, which may affect generalizability.

Conclusion:

The ASCO meeting is anticipated to provide critical insights into new cancer therapies and their potential impact on treatment standards.